Rates and risk factors for suicidal ideation, suicide attempts and suicide deaths in persons with HIV: a protocol for a systematic review and meta-analysis

Holly Wisnousky,1 Nick Lazzara,1 Matt Ciarletta,1 Matt Pelton,1 Vernon M Chinchilli,2 Anna E Ssentongo,3 Paddy Ssentongo 1

ABSTRACT
Introduction The prevalence of HIV/AIDS is high and is associated with psychiatric morbidity and suicide risk. The objective of this study will be to assess the rates of suicidal ideation, suicide attempts and suicide deaths in people living with HIV/AIDS (PLWHA).

Methods and analysis We present a study protocol for a systematic review and meta-analysis of studies reporting the suicidality outcomes (suicidal ideation, suicide attempts and suicide deaths) in PLWHA. PubMed (MEDLINE), Scopus, EMBASE, Cochrane Library, OVID (HEALTH STAR), OVID (MEDLINE), Joanna Briggs Institute EBP Database, Web of Science and PsychINFO databases will be searched from their inception until 1 January 2020. The primary outcome of interest will be the incidence of suicidality in PLWHA. In addition, we will delineate risk factors associated with suicidality in PLWHA. Citations, full-text articles and abstracts will be screened by four reviewers independently. Disagreements will be resolved through discussion. The study methodological quality (or bias) will be appraised using an appropriate tool. Random-effects meta-analysis will be conducted if we find that the studies are very heterogenous. For the suicidality outcome, probability of suicide risk will be reported. Relative risk ratios (with 95% CIs) will be reported for the effects of the risk factors. Potential publication bias will be assessed by conducting Egger’s test and creating funnel plots. We will conduct additional analyses to explore the potential sources of heterogeneity (eg, age, sex and geographical location).

Ethics and dissemination No ethics clearance is required as no primary data will be collected. The results of this systematic review and meta-analysis will be presented at scientific conferences and published in a peer-reviewed journal. The results may inform clinical management of PLWHA and may guide future population-specific interventions. We will search PubMed (MEDLINE), Scopus, EMBASE, Cochrane Library, OVID (HEALTH STAR), OVID (MEDLINE), Joanna Briggs Institute EBP Database, Web of Science and PsychINFO from their inception until 1 January 2020.

PROSPERO registration number CRD42020161501.

BACKGROUND
Since its discovery in the 1980s, HIV continues to carry a significant global burden of disease. While the disease remains incurable, antiretroviral therapy (ART) has been effective in controlling disease progression, improving quality of life and prolonging longevity. In 2018, the World Health Organization (WHO) and the United Nations Program on HIV/AIDS (UNAIDS) approximated that 40 million people globally are living with HIV/AIDS (PLWHA).2 HIV caused an estimated 1 million deaths worldwide and was responsible for the annual 48 disability-adjusted life years per 100000 population.3 4 While the UNAIDS and the WHO provide an effective framework in controlling HIV infection, the current strategies fail to adequately address interventions for the psychosocial burden experienced by PLWHA.

Strengths and limitations of this study
► This will be the first comprehensive systematic review and meta-analysis to synthesise the current literature on the epidemiology of suicidality outcomes in people living with HIV/AIDS.
► We adhered to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines to ensure transparency and reproducibility of the study.
► Heterogeneity in the tools used to assess suicidality outcome may be a limitation.
► Heterogeneity in the cohort selection within each body of work; some studies may limit their work to perinatally infected individuals, pregnant women and/or intravenous drug users.
► To overcome these limitations, we will use meta-regression to statistically explore the sources of heterogeneity in the outcome of interest.
Despite the improved prognosis of HIV, studies continue to find an association between HIV and suicide. Carriero et al reported in 2017 that 6.3% of PLWHAs are at risk for suicide. Likewise, a cross-sectional study found that 78% of minority PLWHAs had suicidal thoughts, and 26% had attempted suicide since diagnosis. Data thus far have shown that patient suicide rates within the first year of HIV diagnosis exceed that of the general population. Furthermore, societal factors such as stigma, discrimination and lack of social support have been implicated. Because the risk factors implicated in suicidality in PLWHAs are multifactorial, identifying the risks correlated to suicidal behaviour in patients with HIV may inform effective preventative measures against suicide. Furthermore, as discussed above, identification of risk factors of suicidal behaviour can improve HIV management in at-risk populations.

Since the introduction of highly active antiretroviral therapy (HAART) in 1996, morbidity and mortality rates have declined in PLWA, although the relationship between HAART and suicide risk remains unclear. A longitudinal study followed 163 PLWHA for 2 years and found that HAART increased CD4 counts and decreased depressive symptoms with a temporal relationship. However, other studies have suggested that HAART combined with clarithromycin or efavirenz can induce a neuropsychiatric reaction, potentially increasing depressive symptoms and suicide risk. To our knowledge, there is no systematic review and meta-analysis that estimates the pooled rates of suicidality in PLWA.

OBJECTIVES
The objective of this study will be to assess the risk factors of suicidal ideation, suicide attempt and suicide deaths in PLWA. The specific review questions will be:

1. What is the global incidence of suicide deaths in PLWA?
2. What is the global prevalence of suicidal ideation and suicide attempt in PLWA?
3. What are the risk factors associated with suicidality outcomes in PLWA?

METHODS
The methods of this protocol are similar to those reported elsewhere. This protocol is being reported in accordance with the reporting guidance provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement protocol (see PRISMA-P checklist in online supplemental file 1).

Eligibility criteria
Participants (population): children, adolescents and adult patients living with HIV. No age and sex constraint.
employment, homelessness, partner presence, percent of population on HAART, regimen of HAART, mean CD4 T cell count, median viral load, proportion of PLWHA with major depression, anxiety and other psychiatric illness, proportion with AIDS and AIDS-associated central nervous system conditions. A PRISMA flow chart detailing the study selection process will be provided.

Assessment of methodological quality of the papers
Methodological quality of studies will be conducted using the Newcastle–Ottawa Quality Assessment Scale, which is a validated tool for assessing quantitative cross-sectional, case–control and cohort studies. Scores of 8 to the maximum score of 9 will be defined as high quality; scores of 5–7 will be defined as intermediate quality, and scores of 1–4 will be defined as low quality. Any discrepancy or disagreements in scoring will be resolved by discussion. Further, sensitivity analysis will be carried out using study quality score.

Data synthesis
The data from each paper (eg, study characteristics, participants, outcomes and findings) will be used to build evidence tables of an overall description of included studies. Incidence and prevalence estimate of suicidality outcome will be presented as cases per 1000 along with 95% confidence intervals (CIs). Relative risk ratios or odds ratios (ORs) with 95% CIs will be used to report the association of suicidality outcome with the risk factors. If feasible and appropriate, data points from primary studies will be used to perform random effects meta-analyses. Since heterogeneity is expected a priori, we will estimate the pooled incidence and its 95% CIs using the random effects model with logarithmic transformation and back transformation. We will use the metafor and metagen functions of the meta package in R Statistical Software for analysis.

The CIs will be calculated using the exact binomial (Clopper-Pearson) interval method. The random effects model assumes the study estimates follow a normal distribution, considering both within-study and between-study variation. Forest plots will be used to visualise the extent of heterogeneity among studies. Quantification of statistical heterogeneity will be accomplished by estimating the variance between studies using $I^2$ statistic, which is the proportion of variation in prevalence estimates that is due to true variation in prevalence rather than sampling (random) error. $I^2$ ranges between 0% and 100% (with values of 0%–25% and 75%–100% indicating low and considerable heterogeneity, respectively). In addition, we will report Tau$^2$ and Cochran Q test with a $p$ value of <0.05 considered statistically significant (heterogeneity). Potential publication bias will be explored using Egger’s test and funnel plots.

Additional analyses
Potential sources of heterogeneity will be explored further by subgroup or meta-regression analyses by using baseline characteristics and methodological covariates. In addition, we plan to conduct analyses by geographical location, age (median), sex (eg, proportion), comorbidities (eg, proportion of major depressive disorder, mean body mass index), CD4 T cell counts (median), HAART (proportion), AIDS (proportion) and quality score of each included study (high vs low/medium score). We will assess publication bias by inspecting the funnel plots for asymmetry and with Egger’s test, with the results considered to indicate potential small study effects when $p$ values <0.10.

Software considerations
All analyses will be conducted in meta-package in R Statistical Software for analysis.

Presentation of results and reporting
The PRISMA guidelines will be followed and the checklist will accompany the publication. Quantitative data will be summarised and presented in tables, forest plots and maps. The prevalence and incidence of suicide in PLWHA will be presented by continents, by study design. We define the prevalence of suicide as the number of existing cases within the described time period, and we define the incidence of suicide as the rate of new cases that occur among cohorts during the described time period. Meta-regression analysis will be reported as absolute differences (per 1000) in the overall probability of suicide. Strength of evidence will be assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework using four levels of quality of evidence: very low, low, moderate and high. We use the following domains GRADE: risk of bias, imprecision, inconsistency, indirectness and publication bias. We will report the overall strength of evidence of the outcome of interest.

Patient and public involvement
Patients were not involved in the development of this systematic review protocol.

DISCUSSION
The systematic review and meta-analysis of studies presented in this protocol will identify, collect and evaluate the existing knowledge underlying the incidence, prevalence and risk factors of suicidality associated with HIV infection. We will report the findings of the systematic review and meta-analysis in accordance with the reporting guidance in the PRISMA statement and the Meta-analysis Of Observational Studies in Epidemiology reporting guideline. The results of the proposed systematic review and meta-analysis will be presented at conferences and published in a peer-reviewed journal. The findings of the proposed review will guide interventions to improve the mental health of people living with HIV with the potential of improving their quality of care and overall survival.
REFERENCES

1 Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008;371:752–9.
2 WHO. Joint United nations programme on HIV/AIDS AIDS. Epidemic update, 2018. Available: http://aidsinfo.unaids.org/
3 Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALY’s): results from the burden of communicable diseases in Europe study, European Union and European economic area countries, 2009 to 2013. Euro Surveill 2018;23.
4 Frank TD, Carter A, Jahagirdar D, et al. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the global burden of diseases, injuries, and risk factors study 2017. Lancet HIV 2019;6:e831–59.
5 Carrié MP, Marcellin F, Fressard L, et al. Suicide risk in a representative sample of people receiving HIV care: time to target most-at-risk populations (ANRS VESPA2 French national survey). PLoS One 2017;12:e0171645.
6 Aldaz P, Moreno-Iribas C, Egués N, et al. Mortality by causes in HIV-infected adults: comparison with the general population. BMC Public Health 2011;11:300.
7 Hentzien M, Cable A, Pugliese P. Factors associated with deaths from suicide in a French nationwide HIV-infected cohort. HIV Med 2018. [Epub ahead of print: 01 Jun 2018]. doi:10.1111/hiv.12633
8 Jia C-X, Mehlm L, Qin P. AIDS/HIV infection, comorbid psychiatric illness, and risk for subsequent suicide: a nationwide register linkage study. J Clin Psychiatry 2012;73:1315–21.
9 O’Donnell JK, Gaynes BN, Cole SR, et al. Ongoing life stressors and suicidal ideation among HIV-infected adults with depression. J Affect Disord 2016;190:322–8.
10 López JD, Shacham E, Brown T. Suicidal ideation persists among individuals engaged in HIV care in the era of antiretroviral therapy. AIDS Behav 2018;22:800–5.
11 Ssentongo P. Prevalence and incidence of new-onset seizures and epilepsy in patients with human immunodeficiency virus (HIV): systematic review and meta-analysis. Epilepsy Behav 2019;93;49–55.
12 Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17–26.
13 Judd FK, Cockram AM, Komiti A, et al. Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: a longitudinal study. Aust N Z J Psychiatry 2000;34:1015–21.
14 Prime K, French P. Neuropsychiatric reaction induced by clarithromycin in a patient on highly active antiretroviral therapy (HAART). Sex Transm Infect 2001;77:297–8.
15 Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf 2006;29:865–74.
16 Bandettini di Poggio M, Anfossi S, Audenino D, et al. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci 2011;18:313–8.
17 Ssentongo P, Lewcun JA, Ssentongo AE, et al. Incidence, risk factors, and outcomes of early postoperative hypoglycemia in surgical patients: a protocol for a systematic review and meta-analysis. Syst Rev 2020;9:158.
18 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
19 Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
20 Peterson J, Welch V, Losos M. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Ottawa Hospital Research Institute; 2011.
21 Schwarzer G. meta: an R package for meta-analysis. R news 2007;7:40–5.
22 Siemieniuk R, Guyatt G. What is GRADE. BMJ Best Practice;10 https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/what-is-grade/.
23 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
24 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000;283:2008–12.